BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Angiogenix, Inc. Initiates Phase II Study Of ACCLAIM(TM) For Chronic Angina


10/19/2005 5:09:27 PM

BURLINGAME, Calif., Dec. 8 /PRNewswire/ -- Angiogenix, Inc., a privately held biopharmaceutical company, today announced the initiation of a Phase II clinical trial of its lead product candidate, ACCLAIM(TM), for the treatment of chronic angina, the chest pain that occurs from inadequate blood flow to the coronary arteries around the heart. ACCLAIM (organic nitrate combined with L-arginine), is an oral proprietary nitrate therapeutic shown to induce coronary vasodilation while overcoming the significant problem of drug tolerance.

Nitrate therapy, the current standard treatment option for patients with chronic angina, has a proven track record of facilitating coronary vasodilation. Vasodilation results in improved blood flow, improved cardiac function and elimination of angina. However, scientific research has demonstrated that ongoing treatment with nitrates results in a condition known as nitrate tolerance, which can lead to reduced vasodilation. Tolerance to nitrates, which develops due to the cellular depletion of L-arginine, significantly limits the effectiveness and usefulness of all existing nitrate drugs. In order to prevent tolerance, patients must include a "nitrate-free interval" in every 24-hour period. During this time, patients do not receive the effective symptom relief associated with nitrate therapy.

ACCLAIM is a proprietary combination of nitrate and L-arginine that provides the beneficial cardiovascular effects of nitrates. Combining L-arginine with organic nitrates prevents the endothelial cell's depletion of L-arginine and the associated problem of nitrate tolerance. By eliminating nitrate tolerance, ACCLAIM allows patients to receive the continuous, 24-hour benefit of a potent nitrate product, thus sustaining the desired vasodilation effect.

"As the first new entry into the $2 billion worldwide nitrate product market in 10 years, ACCLAIM represents a significant improvement in this line of cardiovascular therapy," stated Edmon R. Jennings, Angiogenix' President and Chief Executive Officer. "Nitrate tolerance currently limits the effectiveness of all available nitrate products. By overcoming this serious limitation, ACCLAIM can provide patients the solution they have long needed: a nitrate therapy that provides 24-hour, uninterrupted relief from the debilitating symptoms of angina."

About the Trial

The Phase II, randomized, double-blind, placebo-controlled trial will enroll 170 patients with documented coronary artery disease who suffer from chronic, stable, effort-induced angina. Patients will be given a treadmill exercise test to determine the effect of ACCLAIM on relieving their symptoms of angina. The endpoint for the trial, which will be conducted at cardiology centers in eight countries around the world, is treadmill walking time (TWT) determined from the beginning of the exercise test until the patient develops angina of moderate degree.

About Angiogenix

Angiogenix, Inc. is a biopharmaceutical company focused on the research and development of novel drugs for the treatment of cardiovascular disease, with particular emphasis on disease caused by underlying ischemia. Angiogenix is currently developing two product candidates, ACCLAIM(TM) and Vasotrophin(TM), targeting several of the largest cardiovascular markets.

For more information please visit Angiogenix' website at http://www.angiogenix.com/.

Angiogenix Inc.

CONTACT: Edmon R. Jennings, President and CEO of Angiogenix, Inc.,+1-650-552-0072; or investors, Stephanie Diaz, +1-415-885-2298, or media,Tim Brons, +1-646-319-8981, both of Vida, LLC, for Angiogenix, Inc.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->